| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Boris Blechacz | |
| P2860 | cites work | Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma | Q26824969 |
| The role of inflammation in cholestasis: clinical and basic aspects | Q27694662 | ||
| Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas | Q33581027 | ||
| The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis | Q33886812 | ||
| Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis | Q33977086 | ||
| Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study | Q33985725 | ||
| The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis | Q33989725 | ||
| Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database | Q34077811 | ||
| Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes | Q34093557 | ||
| Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 | ||
| Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study | Q34506385 | ||
| Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study | Q34543074 | ||
| Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution | Q34578979 | ||
| Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions | Q34580542 | ||
| The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. | Q34610145 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. | Q34625677 | ||
| A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice | Q34751963 | ||
| Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis | Q35020936 | ||
| Risk factors for cholangiocarcinoma | Q35074664 | ||
| Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion | Q35097616 | ||
| A new clinically based staging system for perihilar cholangiocarcinoma | Q35124985 | ||
| Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia | Q35524250 | ||
| NCCN clinical practice guidelines in oncology: hepatobiliary cancers | Q35703937 | ||
| Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Q35842729 | ||
| Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma | Q36110741 | ||
| Intrahepatic cholangiocarcinoma in a low endemic area: rising incidence and improved survival | Q36352012 | ||
| Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma | Q36545163 | ||
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes | Q36759538 | ||
| Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center | Q56988660 | ||
| The Blumgart Preoperative Staging System for Hilar Cholangiocarcinoma: Analysis of Resectability and Outcomes in 380 Patients | Q57823376 | ||
| Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment | Q60675548 | ||
| Risk of bile duct carcinogenesis after excision of extrahepatic bile ducts in pancreaticobiliary maljunction | Q73197405 | ||
| Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma | Q75233624 | ||
| EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma | Q80151636 | ||
| Magnetic resonance imaging of cholangiocarcinoma | Q80191471 | ||
| Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome | Q80748891 | ||
| Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins | Q81596311 | ||
| The morbidity, mortality, and prognostic factors for ampullary carcinoma and distal cholangiocarcinoma | Q81609432 | ||
| Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy | Q82419318 | ||
| Preoperative biliary drainage for cancer of the head of the pancreas | Q82495675 | ||
| Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients | Q83378985 | ||
| AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group | Q83979420 | ||
| Exome sequencing of liver fluke-associated cholangiocarcinoma | Q84073724 | ||
| Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality | Q84700863 | ||
| Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival | Q84839184 | ||
| Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma | Q85191683 | ||
| SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions: a single-center, prospective, cohort study | Q85646188 | ||
| Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification | Q36771685 | ||
| Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma | Q37316693 | ||
| Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas | Q37401981 | ||
| Major hepatectomy for perihilar cholangiocarcinoma | Q37639191 | ||
| Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients | Q38023102 | ||
| Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections | Q38051510 | ||
| Liver transplantation for perihilar cholangiocarcinoma | Q38116733 | ||
| Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis | Q38173103 | ||
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma | Q38200403 | ||
| Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. | Q38245162 | ||
| Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. | Q38249070 | ||
| Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience | Q38491635 | ||
| Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. | Q38504053 | ||
| Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma | Q38917883 | ||
| Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience | Q40027818 | ||
| Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis | Q40554841 | ||
| Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line | Q40742867 | ||
| Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. | Q42457047 | ||
| New staging system and a registry for perihilar cholangiocarcinoma | Q43564572 | ||
| Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer | Q43601169 | ||
| Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer | Q43842754 | ||
| Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? | Q44022677 | ||
| Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy | Q44478933 | ||
| Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. | Q44503780 | ||
| Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes | Q44895232 | ||
| A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. | Q45045994 | ||
| Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma | Q45105343 | ||
| Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection | Q45424625 | ||
| Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers | Q45704144 | ||
| Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. | Q45776310 | ||
| Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. | Q45809695 | ||
| Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center | Q46277730 | ||
| MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings | Q46606784 | ||
| Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging | Q46821567 | ||
| Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach | Q47428613 | ||
| The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. | Q48024049 | ||
| Diagnostic and therapeutic utility of single-operator peroral cholangioscopy for indeterminate biliary lesions and bile duct stones | Q48177049 | ||
| Implication of lymph node metastasis detected on 18F-FDG PET/CT for surgical planning in patients with peripheral intrahepatic cholangiocarcinoma. | Q53085794 | ||
| Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. | Q53095265 | ||
| Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. | Q53343044 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| bile duct neoplasm | Q56014549 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2016-12-08 | |
| 2017-01-15 | |||
| P1433 | published in | Gut and liver | Q26841957 |
| P1476 | title | Cholangiocarcinoma: Current Knowledge and New Developments |
| Q64988634 | 18F-FDG PET/CT may be a suitable method for preoperative diagnosis and evaluation of Chinese older patients with hilar cholangiocarcinoma. |
| Q93159908 | Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway |
| Q61796242 | Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies |
| Q89993835 | Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma |
| Q89637491 | Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis |
| Q42363911 | Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report |
| Q92151158 | EUS-FNA is effective for lymph node staging in patients with cholangiocarcinoma |
| Q64990052 | Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. |
| Q57111762 | Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type |
| Q92269441 | Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines |
| Q52649647 | Expression levels of serum miRNA-195 in different types of patients with cholangiocarcinoma and its value to determine the prognosis thereof. |
| Q101166097 | Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles |
| Q90377850 | Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis |
| Q94950681 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study |
| Q91935265 | Linking Helicobacter pylori with gallbladder and biliary tract cancer in Moroccan population using clinical and pathological profiles |
| Q90731814 | Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma |
| Q64117221 | MACC1 promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA |
| Q41692447 | Mass-forming intrahepatic cholangiocarcinoma with portal vein tumor thrombus and bile duct tumor thrombus: A case report |
| Q57112061 | Mirizzi Syndrome: Diagnosis and Management of a Challenging Biliary Disease |
| Q90382152 | Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link |
| Q47603972 | Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview. |
| Q92324382 | Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature |
| Q89625729 | Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma |
| Q90291278 | Overexpression of miR-25 is associated with progression and poor prognosis of cholangiocarcinoma |
| Q91639115 | Overexpression of microRNA-96 is associated with poor prognosis and promotes proliferation, migration and invasion in cholangiocarcinoma cells via MTSS1 |
| Q92970095 | Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications |
| Q89503422 | Percutaneous radiofrequency-assisted liver partition versus portal vein embolization before hepatectomy for perihilar cholangiocarcinoma |
| Q93111074 | Piperlongumine induces autophagy in biliary cancer cells via reactive oxygen species-activated Erk signaling pathway |
| Q98289747 | Platelet-derived PDGF promotes the invasion and metastasis of cholangiocarcinoma by upregulating MMP2/MMP9 expression and inducing EMT via the p38/MAPK signalling pathway |
| Q49606237 | Precancerous and early stage cancer of the bile duct system |
| Q47550861 | Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. |
| Q92277654 | Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis |
| Q57461560 | Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study |
| Q92154739 | Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells |
| Q89487029 | Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma |
| Q58695617 | Recurrent Cholangiocarcinoma in Pregnancy: A Case Report |
| Q33869560 | Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection. |
| Q64075300 | Second primary malignancy in patients with cholangiocarcinoma: a population-based study |
| Q89688140 | Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation |
| Q41345470 | Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma |
| Q30398807 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option |
| Q64962175 | The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development. |
| Q60922992 | The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis |
| Q59133892 | The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium |
| Q90668213 | The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma |
| Q90113516 | Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma |
| Q99578626 | Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells |
| Q61816714 | Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease |
Search more.